What is Still Patentable in the Life Science Industry? Understanding the New Myriad/Mayo Guidelines, and the Impact of the AIA Post-Grant Proceedings

Following the Mayo, Prometheus, and Myriad court decisions in the U.S., the life sciences community has been watching closely to see the breadth of impact these cases have on their industry. In March, the United States Patent and Trademark Office (USPTO) issued its long awaited Guidance for Determining Subject Matter Eligibility of Claims Reciting or Involving Laws of nature, Natural Phenomena, & Natural Products. During this seminar we will discuss how natural product and diagnostic method claims will be examined by the USPTO, as well as, practical advice on the types of claims that may be obtainable in the biotech, pharmaceutical and chemical fields.

Additionally, just 18 months after the AIA post-grant challenges went into effect, the USPTO has already received close to 1100 requests challenging the validity of issued U.S. patents. And the number of petitions continues to increase in the life sciences, medical device, and chemical areas, in what so far has been a very favorable jurisdiction for challengers. In view of this significant change in how the validity of a U.S. patent is being evaluated, we will also discuss best practice examples for successfully handling post-grant challenges.

This seminar will take place in London. Admission is free, but space is limited so please reserve a space as soon as possible. Email.